Evaluation of Organoid-Derived Exosomal microRNA as Liquid Biopsy for Colorectal Cancer: A Multicenter Cross-Sectional Study

  • 1Division of Gastroenterology, Tohoku University Graduate School of Medicine, Sendai, Japan.
  • 2Department of Gastroenterology, Iwaki City Medical Center, Iwaki, Japan.
  • 3Department of Gastroenterology, Japanese Red Cross Sendai Hospital, Sendai, Japan.
  • 4Department of Gastroenterology, Sendai City Hospital, Sendai, Japan.
  • 5Department of Gastroenterology, Osaki Citizen Hospital, Osaki, Japan.
  • 6Department of Gastroenterology, Japan Community Healthcare Organization, Sendai South Hospital, Sendai, Japan.
  • 7Department of Gastroenterology, Iwate Prefectural Isawa Hospital, Oshu, Japan.
  • 8Department of Gastroenterology, Iwate Prefectural Iwai Hospital, Ichinoseki, Japan.
  • 9Department of Gastroenterology, Miyagi Cancer Center, Natori, Japan.
  • 10Department of Gastroenterology, Shirakawa Kosei General Hospital, Shirakawa, Japan.
  • 11Department of Internal Medicine, Kurihara Central Hospital, Kurihara, Japan.
  • 12Department of Gastroenterology, NHO Sendai Medical Center, Sendai, Japan.
  • 13Department of Gastroenterology, South Miyagi Medical Center, Ohgawara, Japan.
  • 14Department of Medical Oncology, Tohoku University Hospital, Sendai, Japan.
  • 15Student Healthcare Center, Institute for Excellence in Higher Education, Tohoku University, Sendai, Japan.

Abstract

Exosomal microRNAs (miRNAs) are candidates for liquid biopsies. Organoid culture systems enable long-term expansion of the colon epithelium. This study evaluated exosomal miRNAs from colorectal cancer organoids for liquid biopsy. Organoids were established from normal colon and colorectal cancer tissues. Exosomes were isolated from conditioned media. miRNAs were extracted from exosomes and compared using microarray analysis. Exosomal miRNAs expression levels in the sera of healthy patients and patients with colorectal cancer were compared at a single institution. The multicenter study was validated using miRNAs upregulated in the serum of colorectal cancer patients, along with exosomal miRNAs reported to be upregulated in colorectal adenoma organoids and sera. A total of 44 exosomal miRNAs were commonly expressed in both normal colorectal epithelial cells and colorectal cancer organoids, whereas 59 were exclusively expressed in colorectal cancer organoids. In a single-center cohort study, two exosomal miRNAs (miR-4284 and miR-5100) were upregulated in the serum of colorectal cancer patients. In a multicenter study, four exosomal miRNAs (miR-4284, miR-5100, miR-1246, and miR-1290) were upregulated in the serum of patients with colorectal cancer. The combination of these four exosomal miRNAs had comparable diagnostic performance to carcinoembryonic antigen, with an area under the curve of 0.75 (95% confidence interval: 0.65-0.83) versus 0.79 (95% confidence interval: 0.70-0.87). Combining the four miRNAs with carcinoembryonic antigen improved diagnostic accuracy, with an area under the curve of 0.82 (95% confidence interval: 0.74-0.89). Exosomal miRNAs derived from colorectal cancer organoids can serve as diagnostic biomarkers for colorectal cancer.

Related Concept Videos